No Data
C-MER MEDICAL (03309.HK) plans to hold a Board of Directors meeting on March 21 to approve the annual performance.
Gelonghui, March 3rd丨C-MER MEDICAL (03309.HK) announced that the Board of Directors meeting will be held on March 21, 2025 (Friday) to address the following matters: 1. Approve the publication of the annual performance for the company and its subsidiaries for the year ending December 31, 2024; 2. Consider the proposal for the payment of the final dividend (if any); and 3. Address any other business.
C-MER MEDICAL: NOTICE OF BOARD MEETING
C-MER MEDICAL (03309.HK) spent 0.8221 million Hong Kong dollars to repurchase 0.4 million shares on February 14.
On February 14, Gelonghui reported that C-MER MEDICAL (03309.HK) announced it spent HKD 0.8221 million to repurchase 0.4 million shares on February 14, 2025, with a repurchase price of HKD 2.03-2.07 per share.
C-MER MEDICAL (03309) spent 0.56888 million Hong Kong dollars to repurchase 0.288 million shares on February 13.
C-MER MEDICAL (03309) announced that on February 13, 2025, it spent 0.56888 million Hong Kong dollars to repurchase 28.8...
C-MER Medical Expects Swing to Loss in 2024
C-MER MEDICAL (03309.HK) expects revenue of approximately 1.9 billion Hong Kong dollars for the 2024 fiscal year.
On February 5, Gelonghui reported that C-MER MEDICAL (03309.HK) announced that, based on the currently available unaudited financial information for the year ending December 31, 2024, excluding the impact of the impairment losses mentioned below, the group expects that the profit attributable to the company's equity holders will be between 50 million and 60 million Hong Kong dollars (2023 fiscal year: 62 million Hong Kong dollars). After excluding the impact of the impairment losses mentioned below, the earnings before interest, taxes, depreciation, and amortization (adjusted EBITDA) will be approximately 300 million Hong Kong dollars (2023 fiscal year: 343.5 million Hong Kong dollars). Due to the group's hospital and clinic...
C-MER Eye Care Holdings (HKG:3309 Investor Three-year Losses Grow to 49% as the Stock Sheds HK$449m This Past Week
